GlassScriptPhysician profile
Daniel Clifford Bowen
NPI 1366548638
$2,231.57
in general payments reported to CMS, 2019-2025
22 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $153 · 2021: $325 · 2022: $613 · 2023: $393 · 2024: $259 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.61 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.63 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Therapeuticsmd, INC. | $242.23 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $199.46 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $197.60 | 2023-2025 | Myfembree |
| Aspira Women'S Health INC | $176.31 | 2022 | |
| Astellas Pharma US INC | $169.07 | 2024-2025 | Veozah |
| Minerva Surgical, INC | $166.83 | 2019-2024 | |
| Hologic Sales and Service, LLC | $161.05 | 2019-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Shield Therapeutics INC | $111.35 | 2023-2025 | Accrufer |
| Channel Medsystems, INC. | $60.26 | 2022 | |
| Pfizer INC. | $55.73 | 2023-2024 | |
| Lupin INC. | $43.47 | 2019-2021 | |
| Novo Nordisk INC | $39.00 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.65 | 2019 | |
| Exeltis, USA INC. | $33.19 | 2021-2023 | Slynd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $23.61 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $23.48 | 2019 | |
| Evofem Biosciences, INC. | $19.16 | 2021 | |
| Gynesonics, INC. | $18.34 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Merck Sharp & Dohme LLC | $16.63 | 2019 | |
| Mission Pharmacal Company | $15.87 | 2019 | |
| Roche Diagnostics Corporation | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.